-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

506.O2.6 506. Bone Marrow Microenvironment: Contribution of Immune Signaling to the Microenvironment

Symposia: Bone Marrow Microenvironment Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Fundamental Science, Acute Myeloid Malignancies, AML, Biological therapies, Bone Marrow Failure Syndromes, Non-Biological therapies, APL, Translational Research, CHIP, genomics, Chemotherapy, Combination therapy, Clinical Research, hematopoiesis, Diseases, immune mechanism, patient-reported outcomes, immunology, Therapies, Immunotherapy, metabolism, computational biology, Myeloid Malignancies, Biological Processes, Pharmacology, Technology and Procedures, molecular biology, Study Population, profiling, Radiation Therapy, Transplantation, Animal model, omics technologies
Sunday, December 11, 2022: 12:00 PM-1:30 PM
260-262 (Ernest N. Morial Convention Center)
Tiago C Luis, PhD, Imperial College London and Sandra Pinho, PhD, The University of Illinois at Chicago
No relevant conflicts of interest to declare.
This session explores the effects of immune cells and inflammation on the bone marrow microenvironment, and in turn, hematopoiesis in normal and diseased models.
12:00 PM

Isabel Weinhaeuser, PhD1*, Diego Pereira-Martins, PhD2*, Luciana Yamamoto de Almeida, PhD3*, Jacobien R Hilberink, BSc4*, Douglas RA Silveira, MD5,6*, Lynn Quek, MBBCh, DPhil, MRCP (UK), FRCPath5,7,8*, César Alexander Ortiz, BSc9*, Antonio R. Lucena-Araujo, Prof. PhD10*, Nienke Visser11*, Emanuele Ammatuna, MD. PhD2*, Gerwin A. Huls, MD, PhD12, Eduardo M Rego, MD, PhD13,14,15,16,17 and Jan Jacob Schuringa, PhD2

1Experimental Hematology, University Medical Center Groningen, Groningen, AL, Netherlands
2Department of Hematology, Cancer Research Centre Groningen, University Medical Centre Groningen, University of Groningen, Groningen, Netherlands
3University of Sao Paulo, Ribeirao Preto, Brazil
4Department of Experimental Hematology, University Medical Center Groningen, Groningen, Netherlands
5School of Cancer and Pharmaceutical Sciences, King's College London, London, United Kingdom
6School of Cancer and Pharmaceutical Sciences, King's College London, London, ENG, United Kingdom
7MRC Molecular Haematology Unit and Oxford Biomedical Research Centre, University of Oxford and Oxford University Hospitals, Oxford, United Kingdom
8Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, United Kingdom
9Center of Cell-based Therapy, University of Sao Paulo, Medical School of Ribeirao Preto, RIBEIRAO PRETO, BRA
10Department of Genetic, Federal University of Pernambuco, Recife - PE, AC, BRA
11Experimental Hematology, University Medical Center Groningen, Groningen, NLD
12University Medical Center, University Groningen, Groningen, GZ, Netherlands
13Division of Hematology, Transfusion Medicine and Cell Therapy, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
14Medical Research Laboratory on Molecular Hematology (LIM-31), University of São Paulo, São Paulo, São Paulo, Brazil
15Center for Cell-based Therapy and Regional Hemotherapy Center, University of Sao Paulo at Ribeirao Preto Medical School, Ribeirao Preto, Sao Paulo, Brazil
16University of Sao Paulo, Sao Paulo, Brazil
17University of São Paulo Medical School, Instituto do Câncer do Estado de São Paulo (ICESP), São Paulo, Brazil

12:15 PM

Kanako Wakahashi, MD, PhD1*, Jiangyan Yu2*, Andrea Rubio-Ponce1*, Stephan Culeman3,4*, Brenda Krishacoumar3,5*, Carina Scholtysek3*, Gerhard Krönke3*, Andreas Schlitzer2* and Andrés Hidalgo1

1Program for Cardiovascular Regeneration, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain
2Quantitative Systems Biology, Life & Medical Sciences Institute, University of Bonn, Bonn, Germany
3Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany
4Immunology of Aging, Leibniz Institute on Aging - Fritz Lipmann Institute, Jena, Germany
5Leibniz-Institut für Analytische Wissenschaften-ISAS-e.V., Dortmund, Germany

12:30 PM

Zhengqi Wang, PhD1, Grace Emmel, MS2*, Hong Seo Lim, PhD3*, Astrid Kosters, PhD4*, Eliver Ghosn, PhD4, Peng Qiu, PhD5* and Kevin D. Bunting, PhD6

1Aflac Cancer and Blood Disorders Center, Emory University School of Medicine, Atlanta, GA
2School of Biological Sciences, Georgia Institute of Technology, Atlanta
3Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta
4Emory Vaccine Center, Lowance Center for Human Immunology, Emory University School of Medicine, Atlanta, GA
5Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta
6Winship Cancer Institute, Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta and Department of Pediatrics, Emory University, Atlanta, GA

12:45 PM

Jayna J Mistry, PhD*, Kira A Young, PhD and Jennifer J J Trowbridge, PhD

The Jackson Laboratory, Bar Harbor, ME

1:00 PM

Anna K Whitehead, MS, BS1,2* and Xinping Yue, MD, PhD1,2*

1Cardiovascular Center of Excellence, LSU Health Sciences Center, New Orleans, LA
2Department of Physiology, LSU Health Sciences Center, New Orleans, LA

1:15 PM

Kostandin V. Pajcini, PhD

Pharmacology and Regenerative Medicine, University of Illinois at Chicago, Chicago, IL

*signifies non-member of ASH